Stufenadaptierte Therapie des Status epilepticus

Der Status epilepticus ist ein häufiger, potenziell lebensbedrohlicher Notfall, der einer unmittelbaren adäquaten Therapie bedarf, da mit seiner Dauer eine höhere Therapierefraktärität sowie neurologische Folgeschäden drohen. Analog der Leitlinie der Deutschen Gesellschaft für Neurologie folgt die Behandlung einem gut etablierten, evidenzbasierten Stufenschema, welches auf Benzodiazepine, anfallssuppressive Medikamente oder Narkotika zurückgreift.

Schlüsselwörter

Neurologie - Intensivmedizin - Krampfanfall - Benzodiazepin - Epilepsie

• Literatur

• 1 Rosenow F, Weber J. S2k-Leitlinie: Status epilepticus im Erwachsenenalter. Nervenarzt 2021; 92: 1002-1030
• 2 Holtkamp M, Knake S, Pataraia E. et al. Neue Terminologie: anfallssuppressives Medikament/ Anfallssuppressivum. Clin Epileptol 2023; 36: 31-82
• 3 Scheffer IE, Berkovic S, Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521
• 4 Strzelczyk A, Ansorge S, Hapfelmeier J. et al. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia 2017; 58: 1533-1541
• 5 Guterman EL, Betjemann JP, Aimetti A. et al. Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurol 2021; 78: 588-595
• 6 Rossetti AO, Logroscino G, Milligan TA. et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008; 255: 1561-1566
• 7 Willems L, Rosenow F, Strzelczyk A. Die Anwendung der Salzburg-Kriterien in der Diagnose des non-konvulsiven Status epilepticus. Klin Neurophysiol 2023; 54: 1-6
• 8 Wellmer J, Quesada CM, Rothe L. et al. Proposal for a magnetic resonance imaging protocol for the detection of epileptogenic lesions at early outpatient stages. Epilepsia 2013; 54: 1977-1987
• 9 Willems LM, Watermann N, Richter S. et al. Incidence, risk factors and consequences of epilepsy-related injuries and accidents: a retrospective, single center study. Front Neurol 2018; 9: 414
• 10 Muhlenfeld N, Stormann P, Marzi I. et al. Seizure related injuries – Frequent injury patterns, hospitalization and therapeutic aspects. Chin J Traumatol 2022; 25: 272-276
• 11 Kienitz R, Kay L, Beuchat I. et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs 2022; 36: 951-975
• 12 Kellinghaus C, Rossetti AO, Trinka E. et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol 2019; 85: 421-432
• 13 Willems LM, Rosenow F, Strzelczyk A. Rezente Entwicklungen in der Therapie des Status epilepticus. Psychopharmakotherapie 2022; 29: 181-186
• 14 Willems LM, Rosenow F, Strzelczyk A. Therapeutische Optionen für Patienten mit Status epilepticus im höheren Lebensalter. Clinical Epileptology 2022; 35: 345-351
• 15 Moalong KMC, Espiritu AI, Fernandez MLL. Efficacy and tolerability of intravenous brivaracetam for status epilepticus: a systematic review. J Neurol Sci 2020; 413: 116799
• 16 Muhlhofer WG, Layfield S, Lowenstein D. et al. Duration of therapeutic coma and outcome of refractory status epilepticus. Epilepsia 2019; 60: 921-934
• 17 Fechner A, Hubert K, Jahnke K. et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia 2019; 60: 2448-2458
• 18 Rosati A, De Masi S, Guerrini R. Ketamine for Refractory Status Epilepticus: A Systematic Review. CNS Drugs 2018; 32: 997-1009
• 19 Alkhachroum A, Der-Nigoghossian CA, Mathews E. et al. Ketamine to treat super-refractory status epilepticus. Neurology 2020; 95: e2286-e2294
• 20 Stetefeld HR, Schaal A, Scheibe F. et al. Isoflurane in (super-) refractory status epilepticus: a multicenter evaluation. Neurocrit Care 2021; 35: 631-639
• 21 Willems LM, Bauer S, Jahnke K. et al. Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review. CNS Drugs 2020; 34: 801-826
• 22 Broomall E, Natale JE, Grimason M. et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76: 911-915
• 23 Rosenthal ES, Claassen J, Wainwright MS. et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol 2017; 82: 342-352
• 24 Vaitkevicius H, Husain AM, Rosenthal ES. et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann Clin Transl Neurol 2017; 4: 411-414
• 25 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56: 1515-1523
• 26 Leitinger M, Trinka E, Gardella E. et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 2016; 15: 1054-1062
• 27 Leitinger M, Beniczky S, Rohracher A. et al. Salzburg consensus criteria for non-convulsive status epilepticus--approach to clinical application. Epilepsy Behav 2015; 49: 158-163
• 28 Roberg LE, Monsson O, Kristensen SB. et al. Prediction of long-term survival after status epilepticus using the ACD score. JAMA Neurol 2022; 79: 604-613